Lo Minastrin Fe is owned by Apil.
Lo Minastrin Fe contains Ethinyl Estradiol; Norethindrone Acetate.
Lo Minastrin Fe has a total of 1 drug patent out of which 0 drug patents have expired.
Lo Minastrin Fe was authorised for market use on 24 July, 2013.
Lo Minastrin Fe is available in tablet, chewable, tablet;oral dosage forms.
Lo Minastrin Fe can be used as prevention of pregnancy.
The generics of Lo Minastrin Fe are possible to be released after 02 February, 2029.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7704984 | APIL | Extended estrogen dosing contraceptive regimen |
Feb, 2029
(5 years from now) |
Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient
Market Authorisation Date: 24 July, 2013
Treatment: Prevention of pregnancy
Dosage: TABLET, CHEWABLE, TABLET;ORAL
3
United States
2
China
2
European Union
1
Canada
1
Mexico
1
Israel
1
Hong Kong
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic